Cargando…

P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT

Detalles Bibliográficos
Autores principales:	Decaux, O., Hulin, C., Perrot, A., Macro, M., Frenzel, L., Diels, J., Perualila, N. J., Ghilotti, F., Haefliger, B., Goldsztajn, E., Vernet, S., Thevenon, J., Willaime, M., Texier, N., Schecter, J. M., Madduri, D., Jackson, C., Valluri, S., Moreau, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429390/ http://dx.doi.org/10.1097/01.HS9.0000846488.02230.86

Ejemplares similares

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
por: Delforge, Michel, et al.
Publicado: (2022)

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
por: Weisel, K., et al.
Publicado: (2022)

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
por: Ri, Masaki, et al.
Publicado: (2022)

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2021)

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
por: Weisel, Katja, et al.
Publicado: (2021)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Munshi, Nikhil, et al.
Publicado: (2023)

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
por: Martin, Thomas, et al.
Publicado: (2023)

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Broijl, A., et al.
Publicado: (2023)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
por: Hillengass, J., et al.
Publicado: (2022)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023)

P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
por: Hulin, C., et al.
Publicado: (2022)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
por: Lin, Y., et al.
Publicado: (2022)

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
por: Merz, Maximilian, et al.
Publicado: (2021)

B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
por: van de Donk, NWCJ, et al.
Publicado: (2022)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
por: Einsele, H, et al.
Publicado: (2022)

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Gay, F, et al.
Publicado: (2022)

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
por: Wu, Liviawati S., et al.
Publicado: (2022)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER
por: Macro, M., et al.
Publicado: (2022)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
por: Mateos, Maria-Victoria, et al.
Publicado: (2022)

Emmy Noether : a tribute to her life and work
Publicado: (1999)

Emmy Noether's wonderful theorem
por: Neuenschwander, Dwight E
Publicado: (2011)

Emmy Noether 1882–1935
por: Dick, Auguste
Publicado: (1981)

Emmy Noether: mathematician extraordinaire
por: Rowe, David E
Publicado: (2021)

EMMI : Instrumento generador de coinversiones y sustitución de importaciones condicionantes para su eficaz operación y desarrollo
por: Ruiz Ramírez, Jesús Octavio
Publicado: (1977)

Empagliflozin in acute myocardial infarction: the EMMY trial( )
por: von Lewinski, Dirk, et al.
Publicado: (2022)

Emmy Noether in Bryn Mawr : Proceedings of a Symposium Sponsored by the Association for Women in Mathematics in Honor of Emmy Noether's lOOth Birthday
por: Srinivasan, Bhama, et al.
Publicado: (1983)

A history of algebra: from Al-Khwārizmī to Emmy Noether
por: Waerden, Bartel Leenert
Publicado: (1985)

Proving it her way: Emmy Noether, a life in mathematics
por: Rowe, David E, et al.
Publicado: (2020)

EMMY: The continued expansion of clinical applications of SGLT2 inhibitors
por: Kotit, Susy
Publicado: (2023)

MINOS: Bt 599 intérieur - Bt 904
Publicado: (1992)

EMMi workshop: anti-matter, hyper-matter and exotica production at the LHC
Publicado: (2015)

Emmi workshop and 26th born symposium three days of strong interactions
por: Blashcke, David, et al.
Publicado: (2009)

flowEMMi: an automated model-based clustering tool for microbial cytometric data
por: Ludwig, Joachim, et al.
Publicado: (2019)

904 Prenatal genetic diagnostic testing during the COVID-19 pandemic
por: Baptiste, Caitlin, et al.
Publicado: (2021)

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023)

Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial
por: Aziz, Faisal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4vgh8jt5aotqdgd77ng6fu1env